Physician profile
Mark Anthony Verra
NPI 1245214063
$3,791.88
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $506 · 2021: $642 · 2022: $1,092.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $747.14 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $555.60 | 2019-2021 | |
| Alcon Vision LLC | $525.78 | 2019-2022 | |
| Horizon Therapeutics Plc | $427.90 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $366.05 | 2019-2020 | |
| Abbvie INC. | $248.34 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $173.77 | 2019-2020 | |
| Shire North American Group INC | $139.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $137.97 | 2019-2022 | |
| Spark Therapeutics, INC. | $124.97 | 2022 | |
| Novo Nordisk INC | $116.80 | 2022 | |
| Oyster Point Pharma, INC. | $94.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $79.48 | 2019 | |
| Kala Pharmaceuticals, INC. | $40.48 | 2019 | |
| Ocular Therapeutix, INC. | $13.28 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Verra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.